1.

Record Nr.

UNINA9911019280003321

Titolo

Defining optimal immunotherapies for type 1 diabetes / / [editors: Gregory Bock and Jamie Goode]

Pubbl/distr/stampa

London, : Novartis Foundation, 2008

ISBN

9786611840525

9781281840523

1281840521

9780470697405

0470697407

9780470697412

0470697415

Descrizione fisica

1 online resource (224 p.)

Collana

Novartis Foundation symposium ; ; v. 292

Disciplina

616.46206

Soggetti

Diabetes - Immunotherapy

Diabetes - Treatment

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes

CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of



autoimmune diabetes to human; Closing remarks; Contributor index; Subject index

Sommario/riassunto

This book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D).Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials.The book integrates information from human and animal studies.The book considers T1D within the broader context of autoimmune disease.The format contains several discussions, which address specific questions and provides